Man Group
RLAY icon

Man Group’s Relay Therapeutics RLAY Stock Holding History

Man Group’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$217K Sell
11,618
-101,225
-90% -$1.47M ﹤0.01% 2256
2026
Q1 		$1.12M Buy
112,843
+25,806
+30% +$231K ﹤0.01% 1792
2025
Q4 		$736K Sell
87,037
-100,784
-54% -$719K ﹤0.01% 1774
2025
Q3 		$980K Sell
187,821
-110,689
-37% -$422K ﹤0.01% 1679
2025
Q2 		$1.03M Buy
298,510
+92,789
+45% +$276K ﹤0.01% 1625
2025
Q1 		$539K Buy
205,721
+32,116
+18% +$126K ﹤0.01% 1770
2024
Q4 		$715K Buy
+173,605
New +$945K ﹤0.01% 1572
2024
Q3 		– Sell
-101,365
Closed -$661K – 2168
2024
Q2 		$661K Sell
101,365
-86,617
-46% -$592K ﹤0.01% 1606
2024
Q1 		$1.56M Buy
187,982
+130,635
+228% +$1.27M ﹤0.01% 1394
2023
Q4 		$631K Buy
+57,347
New +$484K ﹤0.01% 1604

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Man Group's RLAY Position: Q2 2026 in Review

Man Group reduced its Relay Therapeutics (RLAY) stake by 90% in Q2 2026, selling an estimated $1.47M and leaving 11,618 shares worth $217K. The position accounts for ﹤0.01% of the portfolio, ranked #2256.

Man Group first reported a position in RLAY in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.56M in Q1 2024. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Man Group held 11,618 shares of Relay Therapeutics worth $217K as of Q2 2026.
  • Man Group sold 101,225 Relay Therapeutics shares in Q2 2026, an estimated $1.47M.
  • Relay Therapeutics made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #2256 holding.
  • Man Group first reported a position in Relay Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Man Group's Relay Therapeutics position peaked at $1.56M in Q1 2024.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.